At NIH, we maintain a broad and diverse portfolio of biomedical and behavioral research. To turn discovery into health, promising technologies must move from the laboratory into clinical trials, into the marketplace, into the doctor’s office, and into our every-day lives. A key way to transition promising technologies out of the laboratory is through the commercialization process. Continue reading
Well-conducted randomized trials are considered the best method of providing evidence about the safety and efficacy of treatments to improve health. Each year, NIH Institutes and Centers spend an estimated $3-4 billion supporting clinical trial activities. These activities require high-level understanding of human biology, of manufacturing and pre-clinical research, and of regulatory requirements. The process of translating a new therapeutic from discovery to practice can be robust, but … at the same time is long and expensive – and despite the challenges inherent in complex, multi-disciplinary research sometimes too long and too expensive. Continue reading
Over two years ago, NIH rolled out a policy to enhance reproducibility of its supported research through rigor and transparency. Applicants and reviewers were required to devote more attention to four areas: the rigor of the prior research (scientific premise), the rigor of the proposed research (scientific rigor), consideration of biological variables including sex, and the authentication of key biological and/or chemical resources.
When the 21st Century Cures Act was passed later that same year, we were required, amongst other things, to assemble a working group of the Advisory Council to the NIH Director (ACD). These experts were charged with recommending ways to further enhance reproducibility of the research we fund, while being informed by the current policy.
Looking for a grant award you heard about? Go here! Perhaps how many trainees NIH supported? You got it! Research spending on a certain disease? Done! Comparing NIH to another federal funder? Look no further! As you can see, NIH shares a quite diverse array of data associated with our funded grants in a transparent way. But, that does not mean we share everything. Continue reading
Do you have a vision for the future of improving scientific reviews? Are you a first-rate Scientific Leader seeking a career at the Center for supporting the most preeminent biomedical research institutes in the nation and the world? If so, the NIH has the perfect opportunity for you! Continue reading
Remember hearing those stories about how your grand-PIs had to walk five miles, in the snow, uphill, with no shoes just to learn how NIH spent its research budget? Well, believe it or not, but that was just ten years ago. Today, we have the Research, Condition, and Disease Categorization (RCDC) webtool to do this in a blink of an eye. Now, following the official release of Fiscal Year (FY) 2017 data and updated estimates for FYs 2018 and 2019 last month, we wanted to celebrate a successful decade of service. Continue reading
Remembering back to my days as a PI, I can recall myself saying something like “yea, on my NIH grant…” when discussing my research. This may have been okay over coffee, but it is technically incorrect. We hear this confusion a lot. So, we thought it would be worthwhile to remind you about some of the respective roles of institutions and investigators working on an NIH award. Continue reading
We are pleased to announce that stipends will be increased for those supported by Ruth L. Kirschstein National Research Service Awards (NRSAs). As a result, approximately 15,000 NRSA training grant appointees and fellows spanning career stages from undergraduates, graduate students, and postdoctoral researchers will receive a two percent stipend increase for Fiscal Year 2018. Please see the recently released NIH Guide Notice NOT-OD-18-175 for the specific new stipend levels. Continue reading
The most important resource for the successful future of biomedical research is not buildings, instruments, or new technologies – it’s the scientists doing the work. But by now, it’s no longer news that biomedical researchers are stressed – stressed by a hypercompetitive environment that’s particularly destructive for early- and mid-career investigators. But those are the researchers who, if we don’t lose them, will comprise the next generation of leaders and visionaries. Almost 10 years ago, the National Institutes of Health (NIH) took steps to improve funding opportunities for “early stage investigators”, those who were 10 years or less from their terminal research degree or clinical training. Those steps helped, but many stakeholders have concluded that more is needed. Continue reading
I recently wrote an essay for the NIH’s Science, Health, and Public Trust series to encourage a healthy bit of skepticism about clinical studies that solely involve surrogate end-points (e.g. changes in “biomarkers” like blood cholesterol levels or findings on an electrocardiogram). Continue reading